CJC-1295 2/5 mg – long-acting GHRH analogue with DAC

CJC-1295 with DAC is a long-acting GHRH analogue — of the hormone that releases growth hormone. It is based on a modified fragment of GRF (1-29) with four amino acid substitutions, to which DAC (Drug Affinity Complex) has been added — a reactive group that, after administration, binds permanently to blood albumin. This binding protects the peptide from rapid degradation and extends the half-life to approximately 6–8 days.

The difference between “with DAC” and “without DAC” is fundamental. The version without DAC acts briefly (~30 minutes) with isolated, pulsatile GH peaks. The version with DAC maintains a steady, raised background of GH and IGF-1 for many days — with pulsatility preserved, but increased amplitude and baseline. This is why once or twice weekly dosing is sufficient.

It acts on the GHRH receptor in the pituitary — like Sermorelin or the version without DAC. This distinguishes it from the GHRPs / ghrelin mimetics (GHRP-2, Hexarelin, Ipamorelin), which act on the GHS-R1a receptor. In studies the two pathways are combined for a synergistic effect. It is a research peptide with no approval as a medicine; it is studied in the GH/IGF-1 axis, regeneration, body composition and lipolysis.

At Peptology it is supplied as a lyophilised peptide with purity above 99% (HPLC/MS, CoA per batch), in two pack sizes — 2 mg and 5 mg. See also the peptides for recovery and anabolism.

Available pack sizes: 2 mg and 5 mg

CJC-1295 with DAC is available in two lyophilised forms, covering different scales of research work — from individual in vitro runs to larger GH-axis protocols with higher peptide consumption.

Both packs have the same purity > 99% and the same laboratory certificate per batch. The choice of size depends on the scale of the protocol, not on the concentration of the active substance. Peptide Matrix Water™ is recommended for reconstitution.

How it acts — prolonged stimulation of the GHRH axis

With DAC vs without DAC — the difference

The version with DAC (this product) has an albumin-binding group — it acts for days and maintains a steady, raised GH/IGF-1 background, which is why 1–2 administrations per week are sufficient. The version without DAC acts briefly (~30 minutes) with isolated, physiological GH pulses. Since the GHRH and GHS-R1a pathways are independent, in protocols it is combined with a secretagogue (Ipamorelin, GHRP-2, Hexarelin). Data from pharmacological studies, not a claim about the research-grade product.

Pharmacokinetics

• Half-life: ~6–8 days (~5.8–8.1 days in the clinical data)
• Long-acting mechanism: permanent (covalent) binding to albumin via DAC
• GH increase: 2–10-fold after a single dose, sustained for ≥6 days
• IGF-1 increase: 1.5–3-fold, sustained for 9–11 days after a single dose
• After multiple doses: IGF-1 above baseline for up to 28 days
• Schedule: once or twice weekly, subcutaneously (SC)

CJC-1295 with DAC vs without DAC vs Sermorelin

Source: Teichman et al., JCEM (2006); pharmacokinetic data of GHRH analogues. Not a direct head-to-head comparison or a claim about the research-grade product.

Clinical data

In a randomised, double-blind, placebo-controlled phase 1 study (Teichman, JCEM 2006) in healthy adults, a single administration of CJC-1295 with DAC increased GH 2–10-fold for ≥6 days and IGF-1 1.5–3-fold for 9–11 days. After multiple doses, IGF-1 remained above baseline for up to 28 days, with good tolerability (particularly at doses of 30–60 µg/kg). Despite the continuous stimulation, the pulsatility of GH is preserved — the amplitude and baseline increase, without flattening.

The information is scientific and informative, based on phase 1 studies and pharmacological literature; it is not medical advice or a claim about the research-grade product.

Profile at a glance

• Long-acting GHRH analogue — DAC binds the peptide to albumin, half-life ~6–8 days
• 2–10× GH increase and 1.5–3× IGF-1 after a single dose (Teichman, 2006)
• IGF-1 above baseline for up to 28 days after multiple doses
• Preserved GH pulsatility — no flattening of the rhythm
• Available in 2 mg and 5 mg — synergy with GHRPs (Ipamorelin, GHRP-2, Hexarelin)

Adverse effects and safety

Described as well tolerated, with mostly mild and reversible adverse effects; because of the long profile they may last longer.

Related peptides

Catalogue: Peptides for recovery and anabolism · Peptide solutions · Blog

Laboratory protocol — reconstitution, research protocols, storage

Standard protocol, applicable to all research peptides in the Peptology catalogue. For the concentration of the solution (mg/mL) per vial, use the peptide reconstitution calculator.

The 60-second protocol

Quick reference

What you will need

Five rules for reconstitution

Calculating the concentration

Storage

Four mistakes to avoid

CJC‑1295 with DAC - 5 mg - Batch - 0226 - Purity

🚚 Delivery information

• Orders placed by 15:00 are dispatched the same day, delivery in 5–7 working days.
• Shipping with BOX NOW, chosen at checkout. Free shipping from €50, otherwise €2.